Fig. 6

The efficacy of G6D-NAC treatment at PND15. a Survival rate at PND15 from all groups. b Body weight of healthy control, PBS, NAC2, NAC5, G6D-NAC2, and G6D-NAC5 groups. c–f Open field test on motor function and anxiety in healthy controls and G6D-NAC2. There was no significant difference in the distance traveled (c) and velocity (d) among these groups. However, the immobile time (e) and the time spent in the center (f) significantly decreased in the G6D-NAC2 group. *p < 0.05, compared with healthy controls. g Microglial morphology at PND15. Brain slices were stained with IBA1 antibody (microglial marker) and images (× 40) were randomly acquired from the corpus callosum from healthy controls and G6D-NAC2 groups and analyzed using the Neurolucida and Neurolucida Explorer software. The arrows indicated the traced cells. Scale bar, 20 μm. The area of the soma significantly decreased in the G6D-NAC2 group (h). There was no difference in the mean length (i) and the mean nodes (j) of the processes of the microglia among the groups. In addition, there were no differences in the mRNA expression of TNF-α (k), IL-1β (l), IL-10 (m), TGF-β1 (n), and TSPO (o). *p < 0.05, compared with healthy controls